Zacks Investment Research upgraded shares of Synthetic Biologics (NYSEAMERICAN:SYN) from a hold rating to a buy rating in a report issued on Tuesday morning. Zacks Investment Research currently has $0.25 price objective on the stock.

According to Zacks, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. “

Several other research analysts have also commented on the company. HC Wainwright restated a buy rating on shares of Synthetic Biologics in a research report on Friday, May 18th. Griffin Securities lowered Synthetic Biologics from a buy rating to a hold rating in a research report on Wednesday, May 9th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. Synthetic Biologics currently has a consensus rating of Hold and a consensus target price of $17.63.

SYN opened at $2.75 on Tuesday. Synthetic Biologics has a 52 week low of $2.45 and a 52 week high of $36.75.

Synthetic Biologics (NYSEAMERICAN:SYN) last released its quarterly earnings results on Wednesday, August 8th. The company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.40) by $0.35.

A hedge fund recently raised its stake in Synthetic Biologics stock. Blair William & Co. IL raised its position in shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) by 14.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,980,857 shares of the company’s stock after buying an additional 255,096 shares during the period. Blair William & Co. IL owned about 1.54% of Synthetic Biologics worth $631,000 as of its most recent filing with the Securities & Exchange Commission.

About Synthetic Biologics

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

Featured Article: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on Synthetic Biologics (SYN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.